Evidence map›Paper›PMID 35856126›Full record

ReviewFamilial cancer2023

Molecular characterization of an embryonal rhabdomyosarcoma occurring in a patient with Kabuki syndrome: report and literature review in the light of tumor predisposition syndromes.

Sietse M Aukema, Selina Glaser, Mari F C M van den Hout, Sonja Dahlum, Marinus J Blok, Morten Hillmer, Julia Kolarova, Raf Sciot, Dina A Schott, Reiner Siebert and 1 more

Open access · hybridAbstract readReview
In one paragraph

Review in Familial cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Sietse M Aukema *Department of Clinical Genetics, Maastricht University Medical Centre (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands. sietse.aukema@mumc.nl.ORCID 0000-0001-5824-0320
Selina Glaser *Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Mari F C M van den HoutDepartment of Pathology, Research Institute GROW, Maastricht University Medical Center, Maastricht, The Netherlands.
Sonja DahlumInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Marinus J BlokDepartment of Clinical Genetics, Maastricht University Medical Centre (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Morten HillmerInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Julia KolarovaInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Raf SciotDepartment of Pathology, University Hospital, University of Leuven, 3000, Louvain, Belgium.
Dina A SchottDepartment of Clinical Genetics, Maastricht University Medical Centre (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Constance T R M StumpelDepartment of Clinical Genetics, Maastricht University Medical Centre (MUMC+), PO Box 5800, 6202 AZ, Maastricht, The Netherlands. c.stumpel@outlook.com.
Universität Ulm · DEMaastricht University Medical Centre · NLKU Leuven · BEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kabuki syndrome is a well-recognized syndrome characterized by facial dysmorphism and developmental delay/intellectual disability and in the majority of patients a germline variant in KMT2D is found. As somatic KMT2D variants can be found in 5-10% of tumors a tumor predisposition in Kabuki syndrome is discussed. So far less than 20 patients with Kabuki syndrome and a concomitant malignancy have been published. Here we report on a female patient with Kabuki syndrome and a c.2558_2559delCT germline variant in KMT2D who developed an embryonal rhabdomyosarcoma (ERMS) at 10 years. On tumor tissue we performed DNA-methylation profiling and exome sequencing (ES). Copy number analyses revealed aneuploidies typical for ERMS including (partial) gains of chromosomes 2, 3, 7, 8, 12, 15, and 20 and 3 focal deletions of chromosome 11p. DNA methylation profiling mapped the case to ERMS by a DNA methylation-based sarcoma classifier. Sequencing suggested gain of the wild-type KMT2D allele in the trisomy 12. Including our patient literature review identified 18 patients with Kabuki syndrome and a malignancy. Overall, the landscape of malignancies in patients with Kabuki syndrome was reminiscent of that of the pediatric population in general. Histopathological and molecular data were only infrequently reported and no report included next generation sequencing and/or DNA-methylation profiling. Although we found no strong arguments pointing towards KS as a tumor predisposition syndrome, based on the small numbers any relation cannot be fully excluded. Further planned studies including profiling of additional tumors and long term follow-up of KS-patients into adulthood could provide further insights.

Indexed as

Abnormalities, MultipleRhabdomyosarcoma, EmbryonalChildDNAFaceFemaleHematologic DiseasesHumansMutationPhenotypeVestibular DiseasesDNAKabuki syndromeKMT2DMethylationRhabdomyosarcomaTumor predisposition

Identifiers

PMID35856126
PMCPMC9829644
OpenAlexW4285799642

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.